Differences in parp inhibitors for the treatment of ovarian cancer: Mechanisms of action, pharmacology, safety, and efficacy
Articolo
Data di Pubblicazione:
2021
Citazione:
Differences in parp inhibitors for the treatment of ovarian cancer: Mechanisms of action, pharmacology, safety, and efficacy / G. Valabrega, G. Scotto, V. Tuninetti, A. Pani, F. Scaglione. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1661-6596. - 22:8(2021 Apr), pp. 4203.1-4203.16. [10.3390/ijms22084203]
Abstract:
Poly(ADP-ribose) polymerases (PARP) are proteins responsible for DNA damage detection and signal transduction. PARP inhibitors (PARPi) are able to interact with the binding site for PARP cofactor (NAD+) and trapping PARP on the DNA. In this way, they inhibit single-strand DNA damage repair. These drugs have been approved in recent years for the treatment of ovarian cancer. Although they share some similarities, from the point of view of the chemical structure and pharmacodynamic, pharmacokinetic properties, these drugs also have some substantial differences. These differences may underlie the different safety profiles and activity of PARPi.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Efficacy; Niraparib; Olaparib; Ovarian cancer; Rucaparib; Safety; Female; Humans; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors
Elenco autori:
G. Valabrega, G. Scotto, V. Tuninetti, A. Pani, F. Scaglione
Link alla scheda completa:
Link al Full Text: